List of Excipients in Branded Drug KESIMPTA

KESIMPTA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Kesimpta (ofatumumab) uses a compact, preservative-free subcutaneous formulation built around acetate buffering, arginine-based tonicity and solubility control, and polysorbate 80 for protein-interface stabilization. Its commercial opportunity extends beyond excipient supply. The strongest adjacent opportunities are autoinjector technology, cold-chain logistics, adherence services, biosimilar manufacturing, and formulation improvements that preserve the product’s home-use profile.

Kesimpta is a fully human anti-CD20 monoclonal antibody marketed by Novartis for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [1]. The approved maintenance presentation is a 20 mg/0.4 mL single-dose solution for subcutaneous injection.

What excipients are used in Kesimpta?

Kesimpta’s U.S. formulation contains four principal excipient components in water for injection:

Excipient	Formulation role	Commercial relevance
L-arginine	Supports protein solubility and limits aggregation	Important for high-value biologic stability and manufacturability
Glacial acetic acid	pH adjustment	Enables tight pH control in a low-volume injectable
Polysorbate 80	Surfactant that reduces protein adsorption and interface-induced aggregation	Creates supply, oxidation-control and extractables risk
Sodium acetate trihydrate	Buffering and tonicity contribution	Supports pH and osmolality control
Water for injection	Vehicle	Standard parenteral solvent

The product is a clear to slightly opalescent, colorless to yellow solution with a target pH of approximately 5.5. It is supplied without a preservative in a single-use prefilled syringe or Sensoready autoinjector [1].

The formulation does not rely on a complex sugar system such as sucrose or trehalose. That reduces the number of formulation variables but increases the importance of surfactant performance, pH control, protein concentration, container compatibility, and agitation stability.

Why does Kesimpta use arginine, acetate and polysorbate 80?

L-arginine

Arginine is commonly used in protein formulations to improve solubility and reduce self-association. For an antibody intended for subcutaneous delivery, the excipient can help maintain a practical concentration without requiring a larger injection volume.

The commercial value of arginine is linked to consistency rather than exclusivity. Drug manufacturers typically qualify multiple grades and suppliers, but changes in impurity profile, endotoxin burden, bioburden, trace metals, or process residues can require comparability work.

Acetate buffer

Kesimpta uses sodium acetate trihydrate and acetic acid to control pH. Acetate buffers are familiar to biologics manufacturers and are generally compatible with subcutaneous products. The buffer system must remain stable through drug substance manufacture, fill-finish, refrigerated storage, room-temperature excursions, and injection-device contact.

Potential supplier opportunities include pharmaceutical-grade sodium acetate, validated acetic acid, low-endotoxin materials, and dual-source supply programs.

Polysorbate 80

Polysorbate 80 protects the antibody against adsorption to manufacturing equipment, containers and device surfaces. It also reduces aggregation caused by agitation and air-liquid interfaces.

Polysorbate 80 is a more complex risk category than its label description suggests. Hydrolysis can generate free fatty acids, while oxidation can affect both the surfactant and the protein. Supplier-to-supplier variation in fatty-acid composition, peroxide levels, hydroperoxides and degradation products can affect stability.

Commercial opportunities include:

• Low-peroxide polysorbate 80 grades
• Defined or highly characterized surfactant materials
• Oxidation-monitoring assays
• Surfactant-compatible elastomers and syringe components
• Container-closure systems with lower adsorption and extractables
• Formulations using alternative surfactants, subject to comparability and clinical requirements

A substitute surfactant would not be a simple excipient swap. A change could affect aggregation, subvisible particles, immunogenicity risk, syringeability, device performance and regulatory comparability.

What is the Kesimpta dosage form and delivery strategy?

Kesimpta is designed for self-administration after the initial dosing period. The approved regimen is 20 mg by subcutaneous injection at weeks 0, 1 and 2, followed by monthly maintenance beginning at week 4 [1].

The product is available through a prefilled syringe and an autoinjector. This delivery model creates commercial value in three areas:

1. Lower administration burden compared with infusion-based anti-CD20 therapies.
2. Reduced dependence on infusion-center capacity.
3. Greater opportunity for adherence programs, digital reminders, nurse training and specialty-pharmacy support.

The 0.4 mL injection volume is commercially important. Small-volume delivery supports home administration and limits injection discomfort, but it also increases sensitivity to viscosity, needle gauge, plunger force, device tolerances and protein concentration.

What storage and cold-chain requirements affect Kesimpta commercialization?

Kesimpta is stored at 2°C to 8°C, protected from light, and must not be frozen or shaken. The U.S. labeling permits a limited room-temperature period of up to 30 days, after which the product must be used or discarded according to the prescribing information [1].

This creates opportunities for:

• Validated temperature-monitoring systems
• Specialty-pharmacy packaging
• Insulated last-mile shipping
• Patient storage education
• Stability studies supporting controlled room-temperature excursions
• Packaging designed for light protection and shock resistance

A longer allowable room-temperature period could improve patient convenience and reduce logistics cost. That opportunity would require real-time and accelerated stability data, container-closure studies, device compatibility work and regulatory approval.

What patents protect Kesimpta and how does biologic exclusivity work?

Kesimpta is a biologic, so its U.S. regulatory protection is evaluated through the Biologics Price Competition and Innovation Act framework and the FDA Purple Book rather than the conventional small-molecule Orange Book pathway [2,3].

Orange Book status

Kesimpta is not treated like a conventional small-molecule product with Orange Book-listed patents and a Hatch-Waxman Paragraph IV certification process. The key U.S. reference-product protection is biologic exclusivity and patent protection held by the reference-product sponsor.

U.S. regulatory exclusivity

Kesimpta received FDA approval on June 18, 2020. The reference product is generally eligible for 12 years of reference-product exclusivity under the Public Health Service Act, placing the nominal end of the U.S. exclusivity period in June 2032, subject to statutory details and any pediatric-exclusivity adjustment [1,4].

This date is not the same as patent expiration. A biosimilar applicant can face patent litigation, a negotiated license, or a launch decision based on patent risk before or after regulatory exclusivity ends.

Patent strategy

The relevant patent estate can include:

• Ofatumumab composition and antibody sequence claims
• Pharmaceutical composition claims
• Subcutaneous administration methods
• Multiple-sclerosis treatment methods
• Dosing and loading-regimen claims
• Prefilled syringe and autoinjector claims
• Manufacturing and purification claims
• Stability and storage claims

Excipient-specific patents are less likely to create a durable barrier when the excipients are established materials. Commercial protection is more likely to arise from the combination of antibody concentration, buffer system, surfactant level, container, device and administration method.

Are there Paragraph IV challenges to Kesimpta?

A conventional Paragraph IV challenge is not the standard route for Kesimpta because ofatumumab is a biologic. A prospective competitor would generally pursue a 351(k) biosimilar application rather than an abbreviated new drug application under Hatch-Waxman [3,4].

The practical competitive process may involve:

• Patent-list review through the Purple Book
• BPCIA information exchange
• Declaratory or infringement litigation
• Negotiated launch dates
• Interchangeability strategy
• Manufacturing comparability and immunogenicity studies

As of the latest publicly available FDA biologic listings considered here, no FDA-approved ofatumumab biosimilar had displaced Kesimpta in the U.S. market [2]. The absence of an approved biosimilar does not remove future competition risk. Ofatumumab is a commercially attractive target because it has a validated mechanism, a large multiple-sclerosis market and a convenient subcutaneous delivery format.

What formulation patents and manufacturing barriers could delay biosimilar entry?

A biosimilar developer must reproduce the reference product’s critical quality attributes without necessarily using the same formulation process. The main technical barriers include:

• Maintaining antibody monomer content and limiting aggregates
• Matching charge-variant distribution
• Controlling particles and visible particulates
• Demonstrating comparable glycosylation and Fc-related attributes
• Establishing polysorbate stability
• Matching injection performance in the selected device
• Demonstrating compatibility with syringe materials
• Validating container-closure integrity
• Scaling low-bioburden sterile fill-finish operations

The excipients themselves are unlikely to provide the strongest barrier. The more durable barrier is the integrated product system: antibody sequence, formulation, process controls, device, administration instructions and clinical comparability package.

How strong is the Kesimpta patent estate?

The patent estate should be viewed as layered rather than dependent on a single formulation patent.

Protection layer	Strategic value	Likely vulnerability
Ofatumumab molecule and antibody sequence	Very high	Limited for direct biosimilar development if valid claims remain enforceable
Subcutaneous formulation	High	Design-around and obviousness challenges
Loading and maintenance regimen	High in clinical use	Method-of-use litigation and label-scrubbing issues
Autoinjector and prefilled syringe	Moderate to high	Alternative-device designs
Excipient combination	Moderate	Established excipient prior art
Manufacturing process	Moderate to high	Process noninfringement may be difficult to detect
Storage and stability claims	Moderate	Dependent on claim scope and evidence

The strongest commercial protection is likely to come from the biologic reference product, regulatory exclusivity, manufacturing complexity and device integration. Excipient selection alone is unlikely to sustain market exclusivity through the 2030s.

What licensing deals affect Kesimpta?

Novartis obtained rights to ofatumumab from Genmab under a strategic collaboration covering ofatumumab development and commercialization. Genmab disclosed the agreement in 2015, after which Novartis advanced the program in multiple sclerosis and obtained the eventual Kesimpta approval [5].

The licensing history matters because it can affect:

• Royalty economics
• Territory rights
• Development obligations
• Manufacturing control
• Patent prosecution
• Settlement authority
• Long-term margin allocation

Kesimpta’s commercial value is therefore distributed across the product sponsor, the originating antibody developer, device suppliers, contract manufacturers and specialty-distribution channels.

What commercial opportunities exist around Kesimpta excipients?

Pharmaceutical excipient supply

The most immediate opportunities are qualified supply of:

• Low-endotoxin L-arginine
• High-purity sodium acetate trihydrate
• Consistent pharmaceutical-grade acetic acid
• Low-peroxide polysorbate 80
• Extractables-controlled packaging materials

Suppliers that can provide lot-to-lot analytical characterization and regulatory documentation have an advantage over commodity suppliers.

Alternative formulation development

A next-generation formulation could target:

• Longer room-temperature stability
• Lower injection force
• Lower viscosity
• Reduced aggregation after agitation
• Lower dependence on polysorbate 80
• Greater compatibility with wearable or automated delivery systems

Any reformulation would need to preserve clinical performance and demonstrate comparability. A reformulated product could support lifecycle management but could also create patent and regulatory challenges if it is positioned as a distinct product.

Device and packaging

Kesimpta’s commercial model favors reliable self-injection. Opportunities include:

• Connected autoinjectors
• Dose-confirmation systems
• Low-force spring mechanisms
• Needle-shield improvements
• Temperature indicators
• Recyclable secondary packaging
• Human-factors improvements for patients with impaired dexterity

Device patents may create a more practical barrier than excipient patents because they can be linked to patient usability and differentiated product presentation.

Patient-support economics

Home administration supports adherence programs, injection training, specialty-pharmacy services and persistence analytics. These services can influence net commercial value even when the drug’s formulation remains unchanged.

How does Kesimpta compare with infusion-based anti-CD20 therapies?

Kesimpta competes with ocrelizumab, marketed as Ocrevus, and other disease-modifying therapies for multiple sclerosis. Its primary differentiation is monthly self-injection after loading rather than periodic intravenous infusion.

Attribute	Kesimpta	Ocrevus
Active ingredient	Ofatumumab	Ocrelizumab
Administration	Subcutaneous self-injection	Intravenous infusion
Maintenance frequency	Monthly	Approximately every six months
Administration site	Home or healthcare setting	Infusion center or qualified setting
Excipient strategy	Arginine-acetate-polysorbate system	Distinct IV biologic formulation
Primary commercial advantage	Convenience and reduced infusion dependence	Infrequent dosing
Primary commercial risk	Injection adherence and monthly burden	Infusion capacity, reactions and administration cost

The competitive decision depends on patient preference, physician practice, reimbursement, adherence and administration infrastructure. Excipient strategy is commercially relevant because it supports the small-volume, self-administered product architecture.

What revenue exposure does Kesimpta create?

Kesimpta generated more than $1 billion in annual sales by 2023, according to Novartis reporting [6]. That scale increases the value of:

• Formulation continuity
• Dual-source excipient qualification
• Device supply security
• Cold-chain resilience
• Anti-counterfeiting packaging
• Biosimilar monitoring
• Lifecycle-management programs

A significant biosimilar launch could pressure price and volume, while a successful device or storage improvement could extend differentiation. Manufacturing interruptions involving polysorbate 80, sterile fill-finish capacity or autoinjector components could affect supply even if the active antibody remains available.

What is the likely generic or biosimilar launch scenario?

The most credible U.S. entry path is a biosimilar launch after regulatory exclusivity and patent negotiations, rather than a traditional generic launch. Potential scenarios include:

1. An early biosimilar approval followed by a negotiated delayed launch.
2. A post-2032 launch competing primarily on price.
3. A device-differentiated biosimilar with a new autoinjector.
4. A formulation-differentiated biosimilar using a different surfactant or buffer.
5. A limited-label biosimilar that avoids certain patented method-of-use claims.

The principal risks for a biosimilar manufacturer are clinical comparability, analytical similarity, device development, immunogenicity, sterile manufacturing scale and patent litigation.

Key Takeaways

• Kesimpta uses L-arginine, acetate buffering, polysorbate 80 and water for injection in a preservative-free 20 mg/0.4 mL subcutaneous formulation.
• Polysorbate 80 quality and degradation control are the most important excipient-related technical issues.
• The formulation supports home administration, monthly dosing and a small injection volume.
• Kesimpta is governed by the biologic and Purple Book framework, not the conventional Orange Book Paragraph IV system.
• FDA approval occurred on June 18, 2020, creating a nominal 12-year U.S. reference-product exclusivity period through June 2032, subject to statutory adjustments.
• The strongest commercial barriers are likely the antibody, manufacturing process, device integration, clinical regimen and regulatory package.
• Excipient suppliers can pursue opportunities in low-peroxide surfactants, high-purity buffer components, stability analytics and container-closure systems.
• The principal future competitive threat is a 351(k) ofatumumab biosimilar, not a conventional small-molecule generic.

FAQs

Can Kesimpta be reformulated without changing the active antibody?

Yes. A sponsor could develop a formulation with a different buffer, surfactant, concentration or storage profile, but the change would require comparability, stability, device and regulatory evidence.

Is polysorbate 80 essential to Kesimpta?

The approved product uses polysorbate 80 as a stabilizing surfactant. An alternative surfactant could be developed, but it would need to demonstrate equivalent control of aggregation, particles, adsorption and immunogenicity-related risks.

Does Kesimpta have an Orange Book-listed formulation patent?

No conventional Orange Book listing should be expected because Kesimpta is a biologic. Relevant patents are assessed through the biologic patent and Purple Book framework.

Could a biosimilar use different excipients from Kesimpta?

Potentially. A biosimilar does not necessarily need to duplicate every excipient, but differences must be justified through analytical, functional, stability and clinical comparability data.

Which Kesimpta supply-chain component has the highest commercial risk?

The highest practical risks are coordinated rather than isolated: polysorbate 80 quality, sterile fill-finish capacity, autoinjector availability, cold-chain execution and device-component qualification.

References

1. U.S. Food and Drug Administration. (2024). Kesimpta (ofatumumab) prescribing information.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
3. U.S. Food and Drug Administration. (2020). Biologics Price Competition and Innovation Act of 2009.
4. U.S. Code. (2024). 42 U.S.C. § 262: Regulation of biological products.
5. Genmab A/S. (2015). Genmab announces agreement with Novartis for ofatumumab.
6. Novartis AG. (2024). Annual report 2023.